Document Detail

Effect of long-term B-type natriuretic peptide treatment on left ventricular remodeling and function after myocardial infarction in rats.
MedLine Citation:
PMID:  19027731     Owner:  NLM     Status:  MEDLINE    
Although short-term B-type natriuretic peptide (BNP) treatment has been shown to be effective for decompensated congestive heart failure, little is known about the effects of long-term BNP treatment in ventricular remodeling and heart failure in response to myocardial infarction. The aim of the present study was to investigate the effects of long-term BNP treatment on ventricular remodeling and heart failure after myocardial infarction in rats. Myocardial infarction was induced by ligating the left anterior descending coronary artery. The surviving rats were randomly divided into four groups: 1) vehicle-treated myocardial infarction group ('vehicle-treated group'), 2) rats treated with low-dose BNP ('low BNP group'), 3) rats treated with high-dose BNP ('high BNP group'), 4) sham-operated group. Eight weeks after the operation, rats were sacrificed. Compared with the sham-operated group, the vehicle-treated group had significantly higher collagen deposition and angiotensin II levels (P<0.01) and a significantly lower cardiac function (P<0.05). Both BNP-treated groups had significant improvement of these indexes compared with the vehicle-treated group (P<0.01). The high BNP group had significantly less collagen deposition and better cardiac function than the untreated and low BNP groups. Moreover, the mRNA and protein expression of TGFbeta1 and Smad2 in the vehicle-treated group was significantly higher than in the sham-operated group (P<0.01). Both BNP-treated groups had a suppression of TGFbeta1 and Smad2 expression (P<0.01). In conclusion, long-term treatment with BNP prevents ventricular remodeling and deterioration of cardiac function in a dose-dependent fashion, a process that may be associated with the inhibition of TGFbeta1/ Smad2 signaling.
Jiangui He; Yili Chen; Yiyi Huang; Fengjuan Yao; Zhongkai Wu; Shenglong Chen; Lichun Wang; Pingxi Xiao; Gang Dai; Rongsen Meng; Chengxi Zhang; Lilong Tang; Yuli Huang; Zhiming Li
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2008-11-12
Journal Detail:
Title:  European journal of pharmacology     Volume:  602     ISSN:  1879-0712     ISO Abbreviation:  Eur. J. Pharmacol.     Publication Date:  2009 Jan 
Date Detail:
Created Date:  2008-12-16     Completed Date:  2009-10-07     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  1254354     Medline TA:  Eur J Pharmacol     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  132-7     Citation Subset:  IM    
Department of Cardiology, the First Affiliated Hospital of Sun Yat-Sen University, 510080 Guangzhou, China.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Angiotensin II / metabolism
Collagen / metabolism
Myocardial Infarction / drug therapy*,  genetics,  metabolism,  physiopathology*
Natriuretic Agents / pharmacology*,  therapeutic use*
Natriuretic Peptide, Brain / pharmacology*,  therapeutic use*
RNA, Messenger / genetics,  metabolism
Rats, Sprague-Dawley
Smad2 Protein / genetics,  metabolism
Time Factors
Transforming Growth Factor beta1 / genetics,  metabolism
Treatment Outcome
Ventricular Remodeling / drug effects*
Reg. No./Substance:
0/Natriuretic Agents; 0/RNA, Messenger; 0/Smad2 Protein; 0/Transforming Growth Factor beta1; 11128-99-7/Angiotensin II; 114471-18-0/Natriuretic Peptide, Brain; 9007-34-5/Collagen

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Activation of KATP channels increases anticancer drug delivery to brain tumors and survival.
Next Document:  The MCH1 receptor antagonist SNAP 94847 induces sensitivity to dopamine D2/D3 receptor agonists in r...